Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays

ABSTRACT

Argatroban is an antithrombin (AT) drug approved by the U.S. Food and Drug administration for the anticoagulation of patients with heparin-induced thrombocytopenia (HIT) and for patients at risk of HIT undergoing percutaneous coronary intervention. Three generic versions of argatroban (gartban, slovastan, and argaron) are now available. In this study, the anticoagulant bioequivalence of the generic and branded argatrobans were compared using whole blood, platelet-rich plasma, platelet-poor plasma, and antithrombin-deficient plasma using clot-based assays. In addition, biochemical systems related to hemostatic mechanisms that involve thrombin were employed, including thrombin generation, factor Xa generation, platelet activation, fibrinokinetics, and activation of thrombin activatable fibrinolytic inhibitor. Overall, the order of potency was gartban > slovastan > argatroban = argaron; however, the degree of potency differed by assay. Moreover, the inhibition of thrombin by each drug resulted in different mechanisms, as demonstrated in assays dependent on thrombin for enzymatic activation. These data demonstrate that equivalency of generic argatrobans cannot be determined based on their activity in a single clot-based assay. Clinical trials are warranted to evaluate the safety and efficacy of the generic argatroban drugs before use in patients.

Argatroban - thrombin inhibitors - generic - anticoagulant - safety

REFERENCES

• 1 Vender J S, Matthew E B, Silverman I M, Konowitz H, Dau P C. Heparin-associated thrombocytopenia: alternative managements.  Anesth Analg. 1986;  65(5) 520-522
• 2 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(Suppl 3) 188S-203S
• 3 Warkentin T E. Heparin-induced thrombocytopenia: a clinicopathologic syndrome.  Thromb Haemost. 1999;  82(2) 439-447
• 4 Okamoto S, Hijikata A, Kikumoto R et al.. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.  Biochem Biophys Res Commun. 1981;  101(2) 440-446
• 5 Okamoto S, Hijikata A, Kinjo K, Kikumoto R, Okubo K. A novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action.  Kobe J Med Sci. 1975;  21(2) 43-51
• 6 Ikoma H. Development of argatroban as an anticoagulant and antithrombin agent in Japan.  Pathophysiol Haemost Thromb. 2002;  32(Suppl 3) 23-28
• 7 Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805).  Semin Thromb Hemost. 1992;  18(2) 155-160
• 8 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103(14) 1838-1843
• 9 Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805) in experimental antithrombin III-deficient animals.  Thromb Res. 1981;  24(4) 285-298
• 10 Berry C N, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.  Thromb Haemost. 1994;  72(3) 381-386
• 11 Tobu M, Iqbal O, Messmore H L, Ma Q, Hoppensteadt D A, Fareed J. Influence of different anticoagulant agents on fibrinopeptide a generation.  Clin Appl Thromb Hemost. 2003;  9(4) 273-292
• 12 Walenga J M, Ahmad S, Hoppensteadt D, Iqbal O, Hursting M J, Lewis B E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.  Thromb Res. 2002;  105(5) 401-405
• 13 Tamao Y, Yamamoto T, Kikumoto R et al.. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.  Thromb Haemost. 1986;  56(1) 28-34
• 14 Emori T, Hirata Y, Imai T et al.. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell.  Biochem Pharmacol. 1992;  44(12) 2409-2411
• 15 Walenga J M, Fareed D, Schultz C, Neville B, Hoppensteadt D. Argatroban, not lepirudin or bivalirudin, treatment results in the generation of nitric oxide during parenteral administration.  , [abstract] Blood. 2004;  104(11) 512a
• 16 Florian-Kujawski M. Molecular Weight Dependence on the Inhibition of Thrombin Activatable Fibrinolytic Inhibitor (TAFI) by Heparins [dissertation].  Loyola University Chicago  May 2007; 
• 17 Walenga J M, Fareed J, Hoppensteadt D, Emanuele R M. In vitro evaluation of heparin fractions: old vs. new methods.  Crit Rev Clin Lab Sci. 1986;  22(4) 361-389
• 18 Kaiser B, Fareed J, Walenga J M, Hoppensteadt D, Markwardt F. In vitro studies on thrombin generation in citrated, hirudinized and heparinized whole blood.  Thromb Res. 1991;  64(5) 589-596
• 19 Kaiser B, Fareed J, Hoppensteadt D, Birdsong B, Walenga J M, Markwardt F. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems.  Thromb Res. 1992;  65 157-64
• 20 Ahmad S, Jeske W P, Ma Q, Walenga J M, Fareed J. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.  Thromb Res. 2001;  102(2) 143-151
• 21 Demir M, Iqbal O, Untch B, Hoppensteadt D A, Gaikwad B S, Fareed J. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.  Clin Appl Thromb Hemost. 2001;  7(1) 38-43
• 22 Iqbal O, Tobu M, Aziz S et al.. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with HIT undergoing off-pump coronary artery revascularization.  J Card Surg. 2005;  20(1) 42-51
• 23 Food and Drug Administration Center for Drug Evaluation and Research page. FDA website. Available at: http://www.fda.gov/cder/ogd/#Introduction Accessed May 5, 2004
• 24 Fareed J, Jeske W P. Small-molecule direct antithrombins: argatroban.  Best Pract Res Clin Haematol. 2004;  17(1) 127-138
• 25 Monagle P, Barnes C, Ignjatovic V et al.. Developmental haemostasis. Impact for clinical haemostasis laboratories.  Thromb Haemost. 2006;  95(2) 362-372
• 26 Lynch S F, Ludlam C A. Plasma microparticles and vascular disorders.  Br J Haematol. 2007;  137(1) 36-48
• 27 Tan K T, Tayebjee M H, Lim H S, Lip G Y. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.  Diabet Med. 2005;  22(12) 1657-1662